Friday, 15 Dec 2017

You are here

20% Price Hike Among Pfizer Drugs

The increasing cost of drug has been the subject of concern and review - by legislators, reporters and patients.

The Financial Times has reviewed the annual price increases for the 91 drugs in Pfizers portfolio, showing an average price increase by 20 percent in the past year.

This includes Viagra and Lyrica.

Drug pricing has become a highly publicized and contentious issue. Many manufacturers are pledging to be more transparent to address the concerns of payers, patients and politicians.

Price hikes are common.  The cost of three top-selling TNF inhibitors has risen from $18,000 per year in 2000 to nearly $48,000 per year in 2017.

Companies like Sanofi, AbbVie, Allergan and Novo Nordisk have announced their price increases would be in the single-digit percentage range this year.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

PRECISION Subanalyses Question Aspirin Use

The PRECISION trial reported last year that celecoxib appears to be safer than the NSAIDs naproxen or ibuprofen in treating osteoarthritis (OA) and rheumatoid arthritis patients who are at increased cardiovascular risk. New data suggests that adding aspirin may nullify this advantage, according to a study presented at the annual American Heart Association meeting and reported by Medscape.

Physician Visit Times Vary Worldwide

A metanalysis published in BMJ Open shows that for half of the world’s population, primary care doctor visits last less than five minutes and that the range is from 48 seconds in Bangladesh to 22.5 minutes in Sweden (US PCP visit averages at 20 minutes).

Surgical Decompression Ineffective for Subacromial Shoulder Pain

Lancet reports that a common surgical intervention, arthroscopic sub-acromial decompression is ineffective compared to arthroscopy or no surgery at all.

ACR 2017 - Day 1 Highlights

Curtis and colleagues presented a plenary session that analyzed the duration of drug holidays and the risk of subsequent fractures (FX) in women starting bisphosphonates (BP). They looked at 156,236 women taking BP for 3 years (median 2.1 yrs.) and then discontinuing BP.  20% stopped BP for > 6 mos. and 12.7% restarted BP and 11% died. For those off BP for >2 yrs. there was a 40% increased risk of Hip Fx.

The Greatest Rheumatologist - Part I

Who is the greatest rheumatologist? What makes for a great rheum? Is it clinical acumen, scientific achievement, educational prowess or years of unrivaled service or mentoring? Rheumatologists are quite opinionated on this subject and very nostalgic about their mentors and leaders. When I’ve posed this question in small groups, it’s plain to see how moved they become when discussing mentors or peers who influenced them. Thus, I posed this question to many of our leaders and mentors: who do you think of as the greatest rheumatologist?